Texas AG Investigates Lululemon Over "Forever Chemicals" in Activewear 
Chinese Brands Are Taking Over Brazil — And It's Just Getting Started 
AI Deradicalization Tools: How Chatbots Could Help Combat Violent Extremism Online 
CSN's Cement Unit Sale Could Exceed $2 Billion as Global Giants Circle 
Japan Opens Arms Export Floodgates: New Policy Draws Global Defense Interest 
Anthropic Discusses Frontier AI Model Mythos With Trump Administration Despite Pentagon Ban 
Hermès Q1 2026 Sales Miss Expectations Amid Iran War and China Slowdown 
United Airlines Eyes Merger with American Airlines in Potential Industry-Shaping Deal 
Iran War Drives Asia's Plastic Crisis — and a Green Packaging Boom 
Meta Is Building an AI Version of Mark Zuckerberg to Interact With Employees 
Qantas Raises Fuel Cost Forecast Amid Middle East Oil Crisis 
Federal Agencies Secretly Test Anthropic's AI Despite Trump Administration Ban 
OpenAI Addresses Security Vulnerability in macOS App Certification Process 
Jefferies Upgrades Starbucks to Hold as China JV Deal Closes and U.S. Business Shows Signs of Recovery 
Amazon in Advanced Talks to Acquire Globalstar in Starlink Rivalry Move 
DEEPX Partners with Hyundai to Power Next-Gen AI Robots Ahead of IPO 
LIVONIA, Mich., June 01, 2017 -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, including dyslipidemia and NASH, today announced that management will provide a corporate update at LD Micro Invitational, taking place June 6-7 in Los Angeles, California, and at the Jefferies 2017 Global Healthcare Conference, taking place June 6-9, 2017, in New York City.
| LD Micro Invitational | |||
| Date: | Tuesday, June 6th | ||
| Time: | 4:00 pm Pacific Time | ||
| Presenter: | Charles Bisgaier, Ph.D., Chief Scientific Officer | ||
| Location: | Luxe Sunset Boulevard Hotel, Los Angeles, CA | ||
| Jefferies 2017 Global Healthcare Conference | |||
| Date: | Thursday, June 8th | ||
| Time: | 4:00pm Eastern Time | ||
| Presenter: | Lee Golden, MD, Chief Medical Officer | ||
| Location: | Grand Hyatt Hotel, Imperial Ballroom | ||
| Webcast: | http://wsw.com/webcast/jeff105/gemp | ||
About Gemphire
Gemphire is a clinical-stage biopharmaceutical company that is committed to helping patients with cardiometabolic disorders, including dyslipidemia and NASH. We are focused on providing new treatment options for cardiometabolic diseases through our complementary, convenient, cost-effective product candidate gemcabene as add-on to the standard of care especially statins that will benefit patients, physicians, and payors. Gemphire has 3 clinical trials ongoing for homozygous familial hypercholesterolemia (HoFH), heterozygous familial hypercholesterolemia (HeFH)/atherosclerotic cardiovascular disease (ASCVD), and severe hypertriglyceridemia (SHTG) under NCT02722408, NCT02634151, and NCT02944383, respectively with a fourth planned trial in NASH in second half of 2017. Please visit www.gemphire.com for more information.
Contact: Andrew McDonald, Ph.D. LifeSci Advisors, LLC (646) 597-6987 Jeff Mathiesen, CFO Gemphire Therapeutics Inc. (734)-245-1700
